COVID-19: How is your healthcare board coping?

By the Deloitte Board Advisory Practice

Covid-white

As a non-executive director on an NHS Trust Board I know first-hand the speed and effectiveness with which my Board has adopted new ways of working. I have personally been humbled and awed by how our executives have responded. However, it always helpful to understand what other Boards are doing so I’m pleased to be able to feature as our blog this week this article from my colleagues in our Deloitte Board Advisory practice.

Continue reading

Posted on 30/04/2020 | 0 Comments

From evolution to revolution: COVID-19’s impact on the general practice consultation model

By Arvind Madan, Co-founder of eConsult, Practicing GP and Deloitte senior advisor and primary care lead

Covid-sky-blue

In February, we published our report ‘Realising digital-first primary care: Shaping the future of UK healthcare’, discussing the current state, challenges and potential of digital transformation in general practice. We also featured eight good practice case examples with evidence of how technology was helping clinicians manage their workloads more effectively, and improving access and support for patients. One such example is eConsult, co-founded by our colleague Dr Arvind Madan, who is a senior advisor and primary care lead for our Deloitte Public Sector Health practice, and who was also an advisor on our report. As part of our follow-up, we have been catching up on all of our case examples to understand the changes they have experienced in the weeks following the WHO’s declaration of the COVID-19 pandemic on 11 March. This week’s blog follows our previous blog, COVID-19: Accelerating digital transformation in healthcare1, and provides a first-hand account from Dr Madan on how the GP online evolution has become a revolution.

Continue reading

Posted on 24/04/2020 | 0 Comments

The Indian pharmaceutical industry: a time of transition

By Pratik Avhad, Senior Analyst, Insight

Indian-pharma

From being nowhere on the global pharmaceutical (pharma) map in 1970 to playing key role in delivering high-quality and affordable generic drugs worldwide, the Indian pharma industry has come a long way. In the first blog of our series on the ‘pharmacy of the world’, we looked at the factors behind its evolution and highlighted some of the recent domestic and international challenges which have resulted in a period of more volatile and somewhat stagnant growth. This blog explores new initiatives that the industry has embarked on to tackle these challenges and kick-start growth.

Continue reading

Posted on 17/04/2020 | 0 Comments

COVID-19 testing: how it works and why we need it urgently

By Karen Taylor, Director, and Maria João Cruz, Research Analyst, Centre for Health Solutions

Covid-orange

According to the World Health Organization (WHO), rapid testing of patients who meet the suspected case definition for COVID-19 is a priority for determining the clinical management and policy response to control the outbreak.1 Diagnostic testing for COVID-19 is critical to track the spread of this novel virus, understand its epidemiology, inform health managers of each case, and suppress transmission.2 Currently, different countries have implemented different testing strategies, depending on the availability of diagnostics kits and reagents, and on the capacity and capability of the healthcare system. However, there has been a global call to increase the speed and capacity for testing to help isolate cases and flatten the peak. This week’s blog explores the importance of testing, what tests can be done and which are already available.

Continue reading

Posted on 09/04/2020 | 0 Comments

Who will win the race to develop an effective treatment for COVID-19

By Karen Taylor, Director, Centre for Health Solutions

Covid

Our previous reports have highlighted the increasing number of innovations that have led to life-saving and life-enhancing clinical treatments and how, over the past 30 or so years, healthcare has moved from treating infectious or communicable diseases to managing a ‘tidal wave’ of complex age and behaviour related, non-communicable, diseases.1 This transition was made possible by the development and widespread use of vaccines and antibiotics which dramatically reduced the prevalence and improved outcomes for most infectious diseases. Today, this scenario has been turned on its head as people across the world face the unrelenting human and economic impact from a novel, infectious, coronavirus SARS-CoV-2 (named COVID-19 disease). On 11th March the World Health Organisation (WHO) declared COVID-19 a pandemic, and the biopharma industry is now in a race to develop both preventive and therapeutic interventions.

Continue reading

Posted on 06/04/2020 | 0 Comments

COVID-19: Accelerating digital transformation in healthcare

By Karen Taylor and Krissie Ferris, Centre for Health Solutions

Covid-blue

The COVID-19 pandemic is first and foremost a human tragedy, affecting billions of citizens and millions of healthcare staff across the world. The UK Government’s healthcare response has largely been focussed on helping the NHS’s to manage, as far as possible, the predicted increase in hospital demand. This includes social distancing and lockdowns to minimise the spread of infections; building more hospital capacity; and procuring the diagnostic, personal protection equipment and treatments to deal with those who do become infected. Meanwhile, healthcare providers are having to re-consider how best to meet the needs of patients who fear they may have COVID-19, as well as the many others who require new and ongoing support, advice and treatments, while at the same time reducing the need for face to face consultations. As a result, many providers are rapidly embracing digital technologies to triage, support and, where possible, treat patients remotely and help clinicians work more effectively.

Continue reading

Posted on 03/04/2020 | 0 Comments

The Indian pharmaceutical industry: The ‘pharmacy of the world’?

By Pratik Avhad, Senior Analyst, Insight

Indian-pharma

The Indian pharmaceutical (pharma) industry has an annual revenue of US$38 billion – globally it’s the third largest in the world by volume and 11th by value. It comprises over 3,000 pharma companies and 10,500 manufacturing facilities. It also produces drugs at around a third of the US costs and half of the European costs. Moreover, Indian pharma companies supply around 20 per cent of the worlds’ generics and 50 per cent of its vaccines.1,2 This is the first of three blogs exploring the past, present and future of the Indian pharma market. This first blog examines the evolution of the industry, with subsequent ones exploring the transformations now underway, and the likely future for the industry.

Continue reading

Posted on 20/03/2020 | 0 Comments

Fem-Tech: where health and technology meet to transform the future of women's healthcare

By Krissie Ferris, Research Analyst, Centre for Health Solutions

Deloitte-uk-hands-clubbed

As demonstrated in our recent report, ‘Realising digital-first primary care: Shaping the future of UK healthcare’, digital technology is transforming everyone’s relationship with healthcare. It is improving our access to health information and advice, helping us to connect more readily with healthcare professionals, and enabling us to track and manage our own health and wellbeing. However, to date, when it comes to women’s health, innovations have historically been underfunded and under supported. This is set to change with the rise of ‘FemTech’, an umbrella term for wearables, smartphone apps, diagnostics and other products designed to enhance women’s health and wellbeing. In recognition of last Sunday’s International Women’s Day, this week’s blog highlights why increasing investment in FemTech innovation is set to pay dividends!

Continue reading

Posted on 13/03/2020 | 0 Comments

How AI could improve the odds of finding treatments for rare diseases

By Maria João Cruz, Research Analyst, and Dr Francesca Properzi, PhD, Research Manager, Centre for Health Solutions

AI

February 29, a pretty rare date, was this year’s Rare Disease Day, a campaign to raise awareness among the public and policy makers on rare diseases and how they impact the lives of patients and their loved ones.1 Indeed, the advocacy, commitment and tenacity of rare disease patient organisations have played a critical role in elevating ‘rare diseases’ as an emerging global public health priority. Particularly in advocating for legislation to develop drugs and treatment programmes that will meet patients’ needs. In today’s blog we highlight the importance of rare diseases and, in particular, the opportunities that artificial intelligence (AI) tools offer to speed-up the discovery of new treatments.

Continue reading

Posted on 06/03/2020 | 0 Comments

Realising digital-first primary care: Shaping the future of UK healthcare

By Dr Francesca Properzi, PhD, Research Manager and Krissie Ferris, Research Analyst, Centre for Health Solutions

Banner

Primary care, particularly general practice, has been the cornerstone of the NHS since its inception. Over the past decade, increasing demand and capacity challenges have left many staff with unmanageable workloads. In recognition of these challenges, the NHS Long Term Plan, published in January 2019, identifies digital transformation as a national priority. Our latest report, ‘Realising digital-first primary care: Shaping the future of UK healthcare’, highlights the challenges in achieving the policy ambition for a digital-first, primary care service and the key steps needed to speed up the adoption of technology by patients, staff and the wider healthcare system.

Continue reading

Posted on 28/02/2020 | 0 Comments